CalciMedica, Inc. (CALC)
NASDAQ: CALC · Real-Time Price · USD
1.150
0.00 (0.00%)
At close: Oct 22, 2026, 4:00 PM EDT
1.230
+0.080 (6.96%)
After-hours: Oct 22, 2026, 7:50 PM EDT
CalciMedica Employees
CalciMedica had 15 employees as of June 30, 2026. The number of employees did not change compared to the same quarter last year. That makes CalciMedica the 39,183rd largest employer in the world and 5,715th in the United States.
Employees
15
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,416,000
Market Cap
7.85M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 15 | 0 | - |
| Mar 31, 2026 | 16 | 1 | 6.67% |
| Dec 31, 2025 | 16 | 2 | 14.29% |
| Sep 30, 2025 | 15 | 2 | 15.38% |
| Jun 30, 2025 | 15 | 2 | 15.38% |
| Mar 31, 2025 | 15 | 2 | 15.38% |
| Dec 31, 2024 | 14 | 1 | 7.69% |
| Sep 30, 2024 | 13 | -1 | -7.14% |
| Jun 30, 2024 | 13 | -1 | -7.14% |
| Mar 31, 2024 | 13 | 1 | 8.33% |
| Sep 30, 2023 | 14 | 2 | 16.67% |
| Jun 30, 2023 | 14 | 2 | 16.67% |
| Mar 31, 2023 | 12 | 0 | - |
| Sep 30, 2022 | 12 | 0 | - |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Senti Biosciences Holdings | 39 |
| CollPlant Biotechnologies | 39 |
| FibroBiologics | 15 |
| Soligenix | 14 |
| Aprea Therapeutics | 8 |
| CNS Pharmaceuticals | 8 |
| Immuron | 8 |
| Alzamend Neuro | 6 |
CALC News
- 6 weeks ago - CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 7 weeks ago - Calcimedica Inc trading halted, news pending - TheFly
- 1 month ago - CalciMedica to effect 1-for-5 reverse stock split - TheFly
- 1 month ago - CalciMedica Announces One-for-Five Reverse Stock Split - GlobeNewsWire
- 2 months ago - CalciMedica initiated with a Buy at Guggenheim - TheFly
- 2 months ago - CalciMedica Quarterly report: Q2 2026 - Filings
- 2 months ago - CalciMedica announces FDA alignment on Phase 2b Auxora trial design - TheFly
- 2 months ago - CalciMedica, FDA alignment de-risks regulatory path, says H.C. Wainwright - TheFly